Semaglutide biosimilar is under clinical development by Leto Laboratories and currently in Phase II for Diabetes. According to GlobalData, Phase II drugs for Diabetes have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Semaglutide biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Semaglutide biosimilar overview
Semaglutide biosimilar is under development for the treatment of diabetes and weight loss. The therapeutic candidate acts by targeting glucagon like peptide 1 receptor (GLP1R).
Leto Laboratories overview
Leto Laboratories is a biotechnology research and development company that focuses on the development of novel protein drugs. The company’s pipeline products include Il-2-based products such as LTC004 for solid tumors, LTC002 and CY009. Its diversified preclinical oncology pipeline products include LTC 008 treats solid tumors and AB010 targets cancer cachexia; and peptide- and enzyme-based products. The company utilizes its technology platforms including an ultra-high-throughput screening platform and directional protein refolding that carries out molecule design, screening, purification, fixed-point coupling design and dosage form development. It conducts research in areas of protein refolding and cytokine; and has the capabilities to develop polypeptide drugs from design to production. Leto Laboratories has developed various drug discovery platforms for identifying targets and modifying protein molecules in early drug discovery stages. Leto Laboratories is headquartered in Beijing, China.
For a complete picture of Semaglutide biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
